We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Addressing Challenges In Brazil’s Clinical Diagnostics Laboratories

Addressing Challenges In Brazil’s Clinical Diagnostics Laboratories content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

SCIEX has announced that a suite of medical devices has been approved by ANVISA, the Brazilian Health Regulatory Agency, for meeting the market access requirements for medical device products. Brazil’s clinical diagnostics labs face significant challenges with increasing workloads and a greater demand for rapid, accurate results. Accreditation of the devices, which include the SCIEX Triple Quad™ 4500MD LC-MS/MS, QTRAP® 4500MD LC-MS/MS, Topaz™ and Citrine® systems, will enable SCIEX to meet the needs of this market and help clinical labs to attain new quality standards in diagnostic testing.

The Citrine and 4500MD systems are flexible LC-MS/MS systems offering exceptional sensitivity and fast data acquisition, allowing clinical customers to obtain reliable results quickly. The exclusive QTRAP® technology enables unique workflows, providing quantitative and qualitative analysis in a single injection, and allowing the use of highly selective MRM3 quantitation to eliminate interferences. The Citrine System is specifically designed to meet the unique needs of clinical labs that require the greatest sensitivity, the highest throughput, a wide dynamic range, and the ability to employ simplified sample preparation.

The Topaz System is a fully integrated LC-MS/MS system for clinical diagnostics that lowers the barriers to adoption of mass spectrometry, making it accessible to all staff in clinical labs. The system is driven by ClearCore™ MD Software that simplifies and streamlines both workflows and method development, while incorporating features that enhance usability to help new users build proficiency quickly.

All of these systems are designed to maximize uptime in clinical laboratories and support continuous high-throughput operations. They each feature the SCIEX Turbo V™ Source and Curtain Gas™ interface for reliability, sensitivity, and reproducibility in routine clinical testing. These systems provide scientists with the ability to perform multiple assays and quantitate multiple compounds in a single run, resulting in fewer tests, shorter runtimes, and significant cost savings for Brazil’s clinical laboratories.

In addition, the Jasper® LC System, an FDA Class I and CE-marked in vitro diagnostic HPLC system that can operate at high flow rates and high pressures, supports a wide range of applications. Designed for use with SCIEX IVD mass spectrometers, the Jasper HPLC system brings the proven performance and reliability of a SCIEX LC-MS/MS solution to your clinical laboratory.

“It is a tremendous gain for SCIEX to launch our first healthcare-registered products in Brazil,” said Mateus Campos, Director of Sales, Service and Support for Brazil. “We are proud that the reach and analytical depth of such technologies are now available to a major and growing healthcare market. We believe that this approval by ANVISA will lead us to a new era in Brazil’s clinical in vitro diagnostic field.”